(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2011 (30.06.2011)

PCT

(10) International Publication Number
WO 2011/079127 A1

(51) **International Patent Classification**:
A61K 9/48 (2006.01) *A61K 31/535* (2006.01)
A61K 31/655 (2006.01)

(21) **International Application Number**:
PCT/US2010/061588

(22) **International Filing Date**:
21 December 2010 (21.12.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/289,289 22 December 2009 (22.12.2009) US

(71) **Applicant** *(for all designated States except US)*: **ABBOTT LABORATORIES** [US/US]; 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **TONG, Ping** [CN/US]; 6152 Indian Trail, Gurnee, Illinois 60031 (US). **ZHOU, Deliang** [CN/US]; 107 Alexandria Drive, Vernon Hills, Illinois 60061 (US). **ZHANG, Geoff G Z** [US/US]; 1014 Dawes Street, Libertyville, Illinois 60048 (US). **HEEMSTRA, Katherine** [US/US]; 641 W. Grand Avenue, Chicago, Illinois 60654 (US). **FISCHER, Cristina M.** [US/US]; 2821 N. Augusta Drive, Wadsworth, Illinois 60083 (US). **CATRON, Nathaniel** [US/US]; 305 Lakeside Drive, Vernon Hills, Illinois 60061 (US). **SCHMITT, Eric A.** [US/US]; 319 Evergreen Court, Libertyville, Illinois 60048 (US). **SANZGIRI, Yeshwant D.** [US/US]; 1323 Deer Run, Gurnee, Illinois 60031 (US).

(74) **Agents**: **MANZARI, Oona A.** et al.; Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

WO 2011/079127 A1

(54) **Title**: ABT-263 CAPSULE

(57) **Abstract**: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.